TIL 治疗晚期或转移性难治性妇科癌症患者的疗效和安全性

Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria: Signed informed consent must be obtained prior to participation in the study.

* Aged 18-75 years old at the time of consent
* Participants are diagnosed with advanced or metastatic cervical cancer, ovarian cancer, endometrial cancer or breast cancer with radiology and pathology confirmation.
* Failure of two or more Lines of Chemotherapy, or not amenable to curative treatment.
* At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post-resection to extract TIL
* At least one measurable target lesion, that can be accurately measured in at least one dimension with longest diameter ≥20 mm, as defined by RECIST v1.1
* All the chemotherapy or radiotherapy targeting the malignant tumors must be discontinued at least 28 days prior to the tumor resection.
* No serious abnormality of complete blood count and Cardiac, Liver, and Kidney function

Exclusion Criteria:

* Participants who have received organ transplantation or prior cell transfer therapy
* Any active autoimmune disease or history of autoimmune disease, or history of primary immunodeficiency.
* Patients who are taking systemic steroid therapy
* Patients with confirmed HIV infection, or other uncontrolled active viral infections, or serious system infections
* Patients with serious complications of heart, lung, liver, kidney, not suitable for enrollment.
* Patients with suspicious or confirmed brain metastases of any size and any number.
* Suffered from any other malignancy within 5 years (except for fully treated in situ malignant such as breast cancer, bladder cancer, cutaneous basal cell carcinoma or squamous cell carcinoma)
* Patients who are pregnant or breastfeeding
* Any other conditions judged by the researcher will significantly increase the risk of participation.

主要终点：Objective Response Rate · To evaluate the efficacy of TILs in patients with advanced or metastatic refractory malignant gynecological cancer including cervical, ovarian, endometrial and breast carcinoma based on the objective response rate (ORR) as assessed by the Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 · Up to 6 months
次要终点：Disease Control Rate；Progression-Free Survival；Overall Survival；Adverse Events

• TILs infusion · EXPERIMENTAL · Enrolled patients will be infused with their autologous TILs followed by IL-2 administration after post- NMA lymphodepletion

Prospective, multicenter, single-arm, open label, interventional basket trial to evaluate autologous tumor-infiltrating lymphocytes (TILs) infusion followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparation for the treatment of patients with advanced or metastatic refractory gynecological cancer including cervical, ovarian, endometrial and breast carcinoma.